Maiko Maruyama-Inoue1, Shimpei Sato2, Shin Yamane2, Kazuaki Kadonosono2. 1. Department of Ophthalmology, Yokohama City University Medical Center, Yokohama, Japan. maicoo@urahp.yokohama-cu.ac.jp. 2. Department of Ophthalmology, Yokohama City University Medical Center, Yokohama, Japan.
Abstract
PURPOSE: To evaluate the prognosis and response of neovascular age-related macular degeneration (AMD) to anti-vascular endothelial growth factor (VEGF), according to the components of subretinal hyperreflective material (SHRM) classified using optical coherence tomography angiography (OCTA), is the aim of this study. METHODS: We retrospectively studied 39 eyes of 39 consecutive patients with SHRM associated with exudative AMD, who underwent standard examination and multimodal imaging, including fundus photography, optical coherence tomography (OCT), and OCTA. We classified SHRM into type 2 neovascularization (NV), fibrosis, subretinal hyperreflective exudation (SHE), and hemorrhage using OCTA. If compound SHRM was found, components in the foveal center were considered. All patients except one with fibrosis received anti-VEGF treatment for more than 12 months. The best-corrected visual acuity (BCVA) values measured before treatment and at 3, 6, and 12 months after the first injection were compared according to the components of SHRM. RESULTS: Using OCTA, 11 eyes with type 2 NV showed abnormal blood flow and 1 eye with fibrosis showed strong surface projection. Both SHE and hemorrhage components showed projection artifact with no intrinsic flow. However, OCTA enabled eyes with SHE (17 eyes) to be distinguished from those with hemorrhage (10 eyes) because hemorrhage showed masking of choriocapillaris flow. Eyes with SHE showed a significant improvement in the mean logMAR BCVA as compared with the value at the baseline, which was sustained throughout the 12-month follow-up period (p < 0.05). In eyes with type 2 NV and hemorrhage, no significant difference in the mean BCVA values was observed at any follow-up time-point (all, p > 0.05). CONCLUSION: OCTA was useful to noninvasively distinguish SHRM components. It may be important to consider the components of SHRM to predict the visual acuity in patients with AMD.
PURPOSE: To evaluate the prognosis and response of neovascular age-related macular degeneration (AMD) to anti-vascular endothelial growth factor (VEGF), according to the components of subretinal hyperreflective material (SHRM) classified using optical coherence tomography angiography (OCTA), is the aim of this study. METHODS: We retrospectively studied 39 eyes of 39 consecutive patients with SHRM associated with exudative AMD, who underwent standard examination and multimodal imaging, including fundus photography, optical coherence tomography (OCT), and OCTA. We classified SHRM into type 2 neovascularization (NV), fibrosis, subretinal hyperreflective exudation (SHE), and hemorrhage using OCTA. If compound SHRM was found, components in the foveal center were considered. All patients except one with fibrosis received anti-VEGF treatment for more than 12 months. The best-corrected visual acuity (BCVA) values measured before treatment and at 3, 6, and 12 months after the first injection were compared according to the components of SHRM. RESULTS: Using OCTA, 11 eyes with type 2 NV showed abnormal blood flow and 1 eye with fibrosis showed strong surface projection. Both SHE and hemorrhage components showed projection artifact with no intrinsic flow. However, OCTA enabled eyes with SHE (17 eyes) to be distinguished from those with hemorrhage (10 eyes) because hemorrhage showed masking of choriocapillaris flow. Eyes with SHE showed a significant improvement in the mean logMAR BCVA as compared with the value at the baseline, which was sustained throughout the 12-month follow-up period (p < 0.05). In eyes with type 2 NV and hemorrhage, no significant difference in the mean BCVA values was observed at any follow-up time-point (all, p > 0.05). CONCLUSION: OCTA was useful to noninvasively distinguish SHRM components. It may be important to consider the components of SHRM to predict the visual acuity in patients with AMD.
Authors: Tina Ristau; Pearse A Keane; Alexander C Walsh; Alicia Engin; Nils Mokwa; Bernd Kirchhof; Srinivas R Sadda; Sandra Liakopoulos Journal: Ophthalmologica Date: 2013-10-02 Impact factor: 3.250
Authors: Alex S Willoughby; Gui-Shuang Ying; Cynthia A Toth; Maureen G Maguire; Russell E Burns; Juan E Grunwald; Ebenezer Daniel; Glenn J Jaffe Journal: Ophthalmology Date: 2015-07-02 Impact factor: 12.079
Authors: Gui-shuang Ying; Maureen G Maguire; Ebenezer Daniel; Frederick L Ferris; Glenn J Jaffe; Juan E Grunwald; Cynthia A Toth; Jiayan Huang; Daniel F Martin Journal: Ophthalmology Date: 2015-09-15 Impact factor: 12.079
Authors: Gui-shuang Ying; Jiayan Huang; Maureen G Maguire; Glenn J Jaffe; Juan E Grunwald; Cynthia Toth; Ebenezer Daniel; Michael Klein; Dante Pieramici; John Wells; Daniel F Martin Journal: Ophthalmology Date: 2012-10-06 Impact factor: 12.079